Redulla RR, Reddy KR, Faust TW, Dudley-Brown S: A Nurse-Driven Evidence-Based Protocol. Gastroenterol Nurs 38(5): 369-78, October 2015.
Reau N, Fried MW, Nelson DR, Brown RS Jr, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, Reddy KR, Sherman KE.: HCV Council - Critical Appraisal of Data: Recommendations for Clinical Practice in a Rapidly Evolving Therapeutic Landscape. Liver Int. 10, October 2015 Notes: Epub ahead of print.
JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM, Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo PA, Reddy KR: HCV-TARGET Study Group Effectiveness of Simeprevir plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection. Gastroenterology S006-5085(15): 1507-3, October 2015 Notes: Epub ahead of print.
Reddy KR, Ellerbe C, Schilsky M, Stravitz RT, Fontana RJ, Durkalski V, Lee WM: Acute Liver Failure Study Group Determinants of Outcome Among Patients with Acute Liver Failure Listed for Liver Transplantation in the US. Liver Transpl September 2015 Notes: Epub ahead of print.
Singh A, Reddy D, Haris M, Cai K, Reddy KR, Hariharan H, Reddy R.: T1ρ MRI of healthy and fibrotic human livers at 1.5 T.J. Transl Med 8(13), September 2015.
Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, Lee WM, Stolz A, Phillips T, Serrano J, Watkins PB. : Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury. Am J Gastroenterol September 2015 Notes: Epub ahead of print.
Bunchorntavakul C, Reddy KR: Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 42(3): 258-72, August 2015.
Lo Re V 3rd, Carbonari DM, Forde KA, Goldberg D, Lewis JD, Haynes K, Leidl KB, Reddy KR, Roy J, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA : Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiol Drug Saf 24(7): 676-83, July 2015.
Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, McHutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, Sulkowski M. : Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.Hepatology. Hepatology 62(1): 25-30, July 2015.
Lo Re V 3rd, Kallan MJ, Tate JP, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park LS, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR: Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Infect Dis 9:2(3), July 2015.
back to top
Last updated: 02/16/2017
The Trustees of the University of Pennsylvania